Pepscan Therapeutics - Anti-GPCR antibody discovery

Home > Home > Anti-GPCR antibody discovery

News

27-03-2012: PerkinElmer announces collaboration with Pepscan Therapeutics for high throughput synthesis and screening of peptide libraries for drug discovery research

08-02-2012: Pepscan Therapeutics achieves milestones in research collaboration with Janssen R&D Ireland

06-12-2011: Pepscan Therapeutics presents protein mimicry platform for the discovery of anti-GPCR antibodies at International Antibody Conference

10-05-2011: Phylogica and Pepscan enter collaboration to optimise therapeutic phylomer drug candidates

04-04-2011: Pepscan appoints new Chief Business Officer

22-03-2011: Zealand Pharma and Pepscan awarded EU grant of EUR 0.9 million for the joint development of novel peptide drugs

10-03-2011: Pepscan Therapeutics closes a Research and License Agreement aimed at the development of novel vaccines.

03-01-2011: Mercator Therapeutics and Pepscan Therapeutics establish Research and Licensing Collaboration

28-09-2010: Pepscan Therapeutics announces establishment of Scientific Advisory Board

14-09-2010: Pepscan Therapeutics establishes a Research Collaboration with Tibotec Pharmaceuticals

01-09-2010: Oprichter Pepscan gehuldigd bij afscheid

28-04-2010: Pepscan signs partnering agreement with Immunovo for its therapeutic vaccin portfolio

Anti-GPCR antibody discovery

Synthetic immunogens, mimicking the biologically relevant parts of target GPCR's, have proven highly successful in yielding functional antibodies.

Home

> Therapeutic peptides
> Anti-GPCR antibody discovery
> Epitope Mapping